Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer

Fajiu Li, Jie Huang, Dongyuan Ji, Qinghua Meng, Chuanhai Wang, Shi Chen, Xiaojiang Wang, Zhiyang Zhu, Cheng Jiang, Yi Shi, Shuang Liu, Chenghong LiOncology 2017 · DOI

Introduction

Lung cancer remains a leading cause of cancer-related deaths worldwide. As tumors grow, they require an increasing supply of oxygen and nutrients, which they obtain by triggering angiogenesis—the formation of new blood vessels from existing ones. The primary driver of this process is the Vascular Endothelial Growth Factor (VEGF) and its receptor, VEGFR2. While several anti-angiogenic therapies exist, researchers are increasingly looking toward "drug repurposing"—finding new uses for existing, safe medications.

This study explores the potential of Azithromycin, a widely used FDA-approved antibiotic, as a novel inhibitor of tumor angiogenesis in lung cancer.

Targeting the Tumor Infrastructure

A key finding of this research is that Azithromycin specifically targets the cells that build blood vessels, known as Human Lung Tumor-associated Endothelial Cells (HLT-ECs). Interestingly, the drug was found to be significantly more potent against these endothelial cells than against the lung cancer cells themselves.

By suppressing the activation (phosphorylation) of the VEGFR2 receptor, Azithromycin disrupts critical downstream signaling pathways, including PI3K/Akt and Focal Adhesion Kinase (FAK). This molecular interference prevents endothelial cells from adhering, proliferating, and organizing into the complex tube-like structures necessary for functional blood vessels.

Experimental Evidence

The researchers validated Azithromycin's efficacy through both in vitro and in vivo models. In laboratory cultures, the drug inhibited the formation of capillary networks in a dose-dependent manner. This was further confirmed using a directed in vivo angiogenesis assay (DIVAA), where Azithromycin significantly reduced the recruitment of new vessels into implanted angioreactors in mice.

Azithromycin inhibits angiogenesis both in vitro and in vivo. (A-B) Dose-dependent reduction in capillary tube formation. (C-D) Suppression of vessel recruitment in the DIVAA assay.

In lung tumor xenograft models, daily treatment with Azithromycin led to a marked reduction in tumor volume. Histological analysis of these tumors revealed a dramatic decrease in microvessel density, confirming that the drug's anti-tumor effect is primarily driven by its ability to "starve" the tumor of its blood supply.

Key Insights

  • Selective Vulnerability: HLT-ECs are more susceptible to Azithromycin-induced apoptosis than various lung cancer cell lines (e.g., A549, PC-9), suggesting a favorable therapeutic window.
  • Cytoskeletal Disruption: The drug interferes with the assembly of actin stress fibers and focal adhesions, which are essential for the structural integrity and movement of endothelial cells.
  • Potency: The inhibitory effect on tube formation was observed at clinically relevant concentrations, with an IC50 of approximately 3 µM.

Conclusion and Future Directions

The study identifies Azithromycin as a promising candidate for repurposing in lung cancer therapy. By targeting the VEGFR2-mediated signaling pathways in the tumor microenvironment, it offers a dual benefit: inhibiting the growth of new vessels and inducing death in existing tumor-associated endothelial cells.

While these results are compelling, further research is needed to optimize dosing schedules and determine if Azithromycin can enhance the efficacy of current standard-of-care chemotherapies or immunotherapies in clinical settings.

Summary updated

Abstract

Tumor angiogenesis is essential during lung cancer development and targeting angiogenesis may possess a potential therapeutic value. The present study demonstrates that azithromycin, a Food and Drug Administration-approved antibiotic drug, is a novel tumor angiogenesis inhibitor. Azithromycin inhibits capillary network formation of human lung tumor associated-endothelial cells (HLT-ECs) <i>in vitro</i> and <i>in vivo</i>. It significantly inhibits HLT-EC adhesion and vascular endothelial growth factor (VEGF)-induced proliferation of HLT-ECs in a dose-dependent manner without affecting migration. In addition, azithromycin induces apoptosis of HLT-ECs even in the presence of VEGF. Notably, azithromycin inhibits proliferation and induces apoptosis in multiple lung cancer cell lines to a significantly reduced extent compared with in HLT-ECs, suggesting that HLT-ECs are more susceptible to azithromycin treatment. In a lung tumor xenograft model, azithromycin significantly inhibits tumor growth and its anti-tumor activities are achieved by suppressing angiogenesis. Notably, the inhibitory effects of azithromycin on angiogenesis are associated with its ability to suppress VEGF-induced activation of VEGF receptor 2 (VEGFR2), phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), focal adhesion kinase, and disruption of focal adhesion assembly and actin stress fiber formation in HLT-ECs. The present study identifies that azithromycin targets VEGFR2-mediated focal adhesion and PI3K/Akt signaling pathways in HLT-ECs, leading to the suppression of angiogenesis and lung tumor growth.
BibTeX
@inproceedings{li2017azithromycin,
  author = {Fajiu Li and Jie Huang and Dongyuan Ji and Qinghua Meng and Chuanhai Wang and Shi Chen and Xiaojiang Wang and Zhiyang Zhu and Cheng Jiang and Yi Shi and Shuang Liu and Chenghong Li},
  title = {{Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer}},
  booktitle = {Oncology},
  year = {2017},
  doi = {10.3892/ol.2017.6103},
}
Figure